Adma Biologics (NASDAQ: ADMA)
Adma Biologics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Adma Biologics Company Info
ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.
News & Analysis
Why Adma Biologics Stock Crushed the Market on Friday
The network of FDA-approved collection facilities continues to grow.
Why Adma Biologics Was Trouncing the Market Today
The company beat analyst estimates for both revenue and profitability, and raised revenue guidance.
Why Shares of ADMA Biologics Are Climbing Thursday
The company, which focuses on infectious diseases, reported its second-quarter earnings on Wednesday after the markets closed.
Why ADMA Biologics Stock Triumphed on Thursday
Investors were pleasantly surprised by the company's latest set of quarterly figures.
Is ADMA Biologics a Good Coronavirus Stock to Buy Now?
Shares of ADMA Biologics are on the move following the FDA's authorization of convalescent plasma for the treatment of COVID-19 patients.
What You Need to Know About the "Breakthrough" Coronavirus Therapy Heralded by President Trump
Convalescent plasma holds promise for treating COVID-19, but it's still unproven.
Why ADMA Biologics, iBio, and Kamada Are Jumping Today
The FDA's emergency use authorization of convalescent plasma therapy is sending these three stocks higher today.
Why ADMA Biologics Is Tumbling 13.5% Today
The company's secondary stock offering was priced below its prior-day closing price.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.